Min Feng [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
The integration of these targeted therapy agents approved by the FDA into clinical practice is certainly a step ahead in precision medicine in the treatment of cancer [ Figure 5 ] , for it enables the stratification of therapies according to tumor biology and optimizes treatment outcomes for unique types of breast cancer
In case of overdosage, consult your physician
Moreover, many of them must deal with the scars that come after
Retatrutide Retatrutide is a triple agonist (GIP/GLP-1/glucagon receptor) currently in late-stage clinical trials that has shown remarkable weight loss results of up to 24% in Phase 2 studies
Overall, though, its a reliable choice for those looking for a wallet-friendly option